Biocardia Inc (BCDA) Stock Price, Quote & News

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 226 0120

Fax: 650 631 3731

Website: www.biocardia.com

Address:

320 Soquel Way, Sunnyvale, United States

CEOBuysDisclosures May. 22 at 12:20 AM

$BCDA CEO purchased 1,700 shares at $0.92 for a total of $1,570. Altman Peter now owns 293,266 shares. https://ceo-buys.com

1 · Reply

NoQinyoface May. 21 at 7:35 PM

$BCDA From their meeting yesterday it sounds like it will be about 18 months until this really kicks off

2 · Reply

Raycloser May. 19 at 9:11 PM

$BCDA why aren’t other insiders buying

1 · Reply

race2zero May. 19 at 6:21 PM

$BCDA still holding at .875 just for fun, I feel a little pop in the works

0 · Reply

11lp May. 19 at 12:14 PM

$BCDA told you they're a bunch of crooks

0 · Reply

D541 May. 19 at 8:36 AM

$BCDA this is probably gonna go for reverse split / delisted before something substantial happens

0 · Reply

CEOBuysDisclosures May. 19 at 2:25 AM

$BCDA CEO purchased 5,700 shares at $0.92 for a total of $5,244. Altman Peter now owns 291,566 shares. https://ceo-buys.com

1 · Reply

chris_stocks May. 18 at 6:21 PM

$BCDA does anyone know why this is dropping today so much? This is the craziest stock. It gets good news and it falls 10 cents. It gets no news at all and it falls 10 cents.

1 · Reply

NineLinesCat May. 18 at 5:59 PM

$BCDA ...bought more...

0 · Reply

race2zero May. 18 at 5:45 PM

$BCDA I usually only short these type of stocks. I’ve been watching but I’ll jump in here in the .80s as a bull, too tempting

1 · Reply

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

May 20, 2026, 11:40 AM EDT - 2 days ago

BioCardia Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 15, 2026, 4:30 PM EDT - 7 days ago

BioCardia Earnings Call Transcript: Q1 2026

May 15, 2026, 4:30 PM EDT - 7 days ago

BioCardia Earnings release: Q1 2026

May 15, 2026, 4:30 PM EDT - 7 days ago

BioCardia Quarterly report: Q1 2026

May 15, 2026, 8:00 AM EDT - 7 days ago

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

May 13, 2026, 7:00 AM EDT - 9 days ago

BioCardia Slides: Corporate presentation

May 11, 2026, 5:10 PM EDT - 11 days ago

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

2026-05-08T18:14:28.000Z - 14 days ago

BioCardia provides update on Helix pre-submission meeting with FDA

Apr 28, 2026, 7:00 AM EDT - 24 days ago

BioCardia Slides: Corporate presentation

2026-04-20T13:09:35.000Z - 4 weeks ago

BioCardia reports ‘positive’ outcome in consult with Japan’s PMDA for CardiAMP

Apr 20, 2026, 8:00 AM EDT - 4 weeks ago

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

2026-04-02T14:20:13.000Z - 7 weeks ago

BioCardia files request for meeting with FDA to discuss CardiAMP pathway

Mar 24, 2026, 4:30 PM EDT - 2 months ago

BioCardia Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 2 months ago

BioCardia Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 2 months ago

BioCardia Annual report: Q4 2025

Mar 24, 2026, 4:05 PM EDT - 2 months ago

BioCardia Reports 2025 Business Highlights and Financial Results

Mar 19, 2026, 7:47 PM EDT - 2 months ago

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

2026-03-17T10:05:13.000Z - 2 months ago

BioCardia’s pre-submission package for Helix catheter approved by FDA

2026-03-03T13:42:33.000Z - 2 months ago

BioCardia reports results from Phase III trial for ischemic heart failure

2026-02-10T14:21:02.000Z - 3 months ago

BioCardia files pre-submission for FDA approval of Helix catheter

Feb 10, 2026, 9:15 AM EST - 3 months ago

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

2025-12-16T13:10:48.000Z - 5 months ago

BioCardia completed third preliminary clinical consultation with Japan’s PMDA

Dec 16, 2025, 8:00 AM EST - 5 months ago

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

2025-12-03T13:16:10.000Z - 6 months ago

BioCardia appoints Slosman to its Board of Directors

NSPR

Dec 1, 2025, 8:30 AM EST - 6 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

2025-11-24T13:41:01.000Z - 6 months ago

BioCardia appoints Farhan Shahab as VP, quality

Nov 24, 2025, 8:15 AM EST - 6 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 12, 2025, 4:40 PM EST - 6 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 12, 2025, 4:30 PM EST - 6 months ago

BioCardia Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 6 months ago

BioCardia Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 6 months ago

BioCardia Quarterly report: Q3 2025

2025-11-10T13:47:11.000Z - 6 months ago

BioCardia first patient enrolled at Henry Ford Health for Phase 3 CardiAMP

Nov 5, 2025, 7:29 PM EST - 7 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Nov 3, 2025, 7:00 AM EST - 7 months ago

BioCardia Proxy statement: Proxy Filing

2025-10-30T12:26:50.000Z - 7 months ago

BioCardia announces patient enrolled at Wisconsin School for CardiAMP trial

2025-10-02T12:10:31.000Z - 8 months ago

BioCardia regains compliance with Nasdaq listing requirements

Oct 2, 2025, 8:00 AM EDT - 8 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

2025-09-22T12:05:28.000Z - 8 months ago

BioCardia announces preliminary consultation with Japan PDMA on CardiAMP results

2025-09-18T13:25:16.000Z - 8 months ago

BioCardia prices 4.8M shares at $1.25 in public offering

Sep 18, 2025, 9:15 AM EDT - 8 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

2025-09-18T11:07:02.000Z - 8 months ago

BioCardia announces CardiAMP Cell Therapy results

Sep 18, 2025, 7:00 AM EDT - 8 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 17, 2025, 8:00 AM EDT - 8 months ago

BioCardia Registration statement: Registration Filing

2025-09-16T13:10:38.000Z - 8 months ago

BioCardia files to sell 2.8M shares of common stock, warrants

Sep 16, 2025, 8:00 AM EDT - 8 months ago

BioCardia Registration statement: Registration Filing

Sep 4, 2025, 9:00 AM EDT - 9 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

2025-08-13T12:20:49.000Z - 10 months ago

BioCardia, CART-Tech enter exclusive agreement for Heart3D Fusion Imaging

Aug 11, 2025, 4:30 PM EDT - 10 months ago

BioCardia Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

BioCardia Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

BioCardia Earnings release: Q2 2025

2025-08-11T13:21:22.000Z - 10 months ago

BioCardia reports Q2 EPS (40c) vs. (88c) last year

2025-08-11T13:21:09.000Z - 10 months ago

BioCardia sees cash runway into October

Aug 11, 2025, 9:15 AM EDT - 10 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 6, 2025, 3:18 PM EDT - 10 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 4, 2025, 6:00 AM EDT - 10 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

Jul 9, 2025, 8:00 AM EDT - 11 months ago

BioCardia Registration statement: Registration Filing

May 21, 2025, 3:40 PM EDT - 1 year ago

BioCardia Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q1 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 9, 2025, 4:28 PM EDT - 1 year ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing

Apr 11, 2025, 9:15 AM EDT - 1 year ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Annual report: Q4 2024

Mar 31, 2025, 1:39 PM EDT - 1 year ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 1 year ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 1 year ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 1 year ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Quarterly report: Q3 2024

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing

Jul 17, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 2 years ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q1 2024

May 14, 2024, 4:02 PM EDT - 2 years ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 2 years ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 30, 2024, 3:00 PM EDT - 2 years ago

BioCardia Transcript: Status Update

Apr 25, 2024, 9:00 AM EDT - 2 years ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 15, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Annual report: Q4 2023

Mar 27, 2024, 4:00 PM EDT - 2 years ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 14, 2024, 7:00 AM EST - 2 years ago

BioCardia Registration statement: Registration Filing

Feb 8, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Jan 31, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

CEOBuysDisclosures May. 22 at 12:20 AM

$BCDA CEO purchased 1,700 shares at $0.92 for a total of $1,570. Altman Peter now owns 293,266 shares. https://ceo-buys.com

1 · Reply

NoQinyoface May. 21 at 7:35 PM

$BCDA From their meeting yesterday it sounds like it will be about 18 months until this really kicks off

2 · Reply

Raycloser May. 19 at 9:11 PM

$BCDA why aren’t other insiders buying

1 · Reply

race2zero May. 19 at 6:21 PM

$BCDA still holding at .875 just for fun, I feel a little pop in the works

0 · Reply

11lp May. 19 at 12:14 PM

$BCDA told you they're a bunch of crooks

0 · Reply

D541 May. 19 at 8:36 AM

$BCDA this is probably gonna go for reverse split / delisted before something substantial happens

0 · Reply

CEOBuysDisclosures May. 19 at 2:25 AM

$BCDA CEO purchased 5,700 shares at $0.92 for a total of $5,244. Altman Peter now owns 291,566 shares. https://ceo-buys.com

1 · Reply

chris_stocks May. 18 at 6:21 PM

$BCDA does anyone know why this is dropping today so much? This is the craziest stock. It gets good news and it falls 10 cents. It gets no news at all and it falls 10 cents.

1 · Reply

NineLinesCat May. 18 at 5:59 PM

$BCDA ...bought more...

0 · Reply

race2zero May. 18 at 5:45 PM

$BCDA I usually only short these type of stocks. I’ve been watching but I’ll jump in here in the .80s as a bull, too tempting

1 · Reply

Klinsmann May. 18 at 4:10 PM

$BCDA maybe an unpopular opinion today, but they have a lot of drugs = great news in the pipeline for the coming weeks… just read the PR’s. FDA approval, pma approval, several drugs in their portfolio. And the RS nonsense is a lie!

2 · Reply

Wut May. 18 at 2:25 PM

$BCDA about time for another R/S followed by some fund raising at y'all's expense 🫣

0 · Reply

Klinsmann May. 16 at 1:10 PM

$BCDA because there won’t be “big dilution coming”

1 · Reply

Raycloser May. 16 at 5:04 AM

$BCDA I don’t understand why Altman would buy shares right now if a big dilution is coming

0 · Reply

Jusme May. 16 at 1:21 AM

$BCDA “For the second quarter of 2026, looking ahead, we expect to complete 1 or more transactions that will fund Japan PMDA submission for approval and the CardiAMP Heart Failure II trial.” ?? Hopefully these are non dilutive but won’t stake my life, even my lunch, on it.

0 · Reply

CEOBuysDisclosures May. 15 at 11:50 PM

$BCDA CEO purchased 5,100 shares at $1.02 for a total of $5,202. Altman Peter now owns 285,866 shares. https://ceo-buys.com

0 · Reply

EarningsInsider May. 15 at 9:15 PM

https://www.marketbeat.com/earnings/reports/2026-5-15-biocardia-inc-stock/ $BCDA BioCardia Earnings Transcript

0 · Reply

chris_stocks May. 15 at 9:06 PM

$BCDA the one good thing about this is that the stock is now super cheap to buy a lot of shares. Lol. Also that conference call did not really give any new information that I'm aware of

0 · Reply

Klinsmann May. 15 at 7:12 PM

$BCDA the numbers gonna improve extremely on the next updates from the fda. Still think that the call will bring more than just the pure numbers…

0 · Reply

StocktwitsEarnings May. 15 at 6:30 PM

$BCDA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 64.41% YoY • BioCardia expects operating losses and negative cash flows to continue through the next several years, with current cash not sufficient to fund planned expenditures beyond June 2026, requiring additional capital.

0 · Reply

chris_stocks May. 15 at 5:29 PM

$BCDA I honestly do not know why anybody thought the earnings report was going to be any different than it was. It's like the people who dumped their shares had no idea what the stock was that they invested in.

3 · Reply

Raycloser May. 15 at 3:59 PM

$BCDA the report isn’t being well received

1 · Reply

Market Cap	10.47M
Revenue (ttm)	0.00
Net Income (ttm)	-8.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	65,300
Avg Vol	181,466
Day's Range	N/A - N/A
Shares Out	11.38M
Stochastic %K	24%
Beta	0.56
Analysts	Sell
Price Target	$15.50